| 1 |
32134850 | The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. | 2020 Mar/Apr |
2 |
| 2 |
30838456 | Serotonin and Norepinephrine Reuptake Inhibitors. | 2019 |
6 |
| 3 |
28866861 | Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. | 2018 Jun |
1 |
| 4 |
28229443 | [Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor]. | 2017 Mar 1 |
1 |
| 5 |
26331791 | Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. | 2016 May |
2 |
| 6 |
23221858 | Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. | 2013 Mar |
1 |
| 7 |
23541126 | Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. | 2013 Jun |
1 |
| 8 |
21840145 | Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. | 2012 Jan 10 |
2 |
| 9 |
21099743 | Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. | 2011 Feb |
3 |
| 10 |
19919295 | Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. | 2010 Jan |
1 |
| 11 |
20098230 | Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. | 2010 Jan |
1 |
| 12 |
19001559 | The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. | 2009 Feb |
3 |
| 13 |
19557107 | Desvenlafaxine in the treatment of major depressive disorder. | 2009 |
1 |
| 14 |
19593180 | Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. | 2009 Aug |
4 |
| 15 |
19629022 | Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. | 2009 |
1 |
| 16 |
18698015 | Desvenlafaxine: another "me too" drug? | 2008 Oct |
1 |
| 17 |
18809731 | An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. | 2008 Dec |
1 |
| 18 |
19057238 | Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. | 2008 Nov |
4 |
| 19 |
16642541 | CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. | 2006 Jun |
1 |
| 20 |
16958828 | CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. | 2006 Oct |
2 |